Evaluation of adipokines and inflammatory mediator expression levels in patients with periodontitis and peri-implantitis: a cross-sectional study

İşler, Sıla Çağrı; Soysal, Fatma Selda Öz; Özcan, Erkan; Saygun, N; Unsal, Fatma; Barış, Emre; Ilıkçı, Rahşan

doi:10.1007/s00784-020-03678-7

Cited by 7 publications

(6 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A deeper knowledge of the inflammatory mechanisms, protein biomarkers, and cytokines involved in peri‐implant disease progression could be crucial for clinicians, since this can guide the early treatment through nonsurgical methods (e.g., immunomodulators and cytokine inhibitors) and surgical preventive approaches that may improve the stability of peri‐implant soft tissue structures that protect the subsequent peri‐implant crestal bone. Several studies evidenced that biomarkers for IL‐1ß, IL‐ 6, IL‐17, matrix metalloproteinases, VEGF, TNF‐α, and adipokines are significantly higher at peri‐implant diseased sites' crevicular fluid samples when compared to healthy samples 11,21,26–29 . Remarkably, certain studies have pointed that those pro‐inflammatory biomarkers are associated to thin PSP features presenting inadequate keratinized mucosa (KM) width, reduction of mucosal attachment, and higher marginal recession levels 20,21 .…”

Section: Inflammatory Mechanisms and Disease Progression At The Soft ...mentioning

confidence: 99%

“…Several studies evidenced that biomarkers for IL-1ß, IL-6, IL-17, matrix metalloproteinases, VEGF, TNF-α, and adipokines are significantly higher at peri-implant diseased sites' crevicular fluid samples when compared to healthy samples. 11,21,[26][27][28][29] Remarkably, certain studies have pointed that those proinflammatory biomarkers are associated to thin PSP features presenting inadequate keratinized mucosa (KM) width, reduction of mucosal attachment, and higher marginal recession levels. 20,21 Moreover, some studies have also evidenced that the pro-inflammatory biomarker expression at peri-implant diseased sites was significantly reduced by antibacterial and anti-inflammatory therapies and also after soft tissue grafting techniques that improved the PSP.…”

Section: Inflammatory Protein Biomarkersmentioning

confidence: 99%

See 1 more Smart Citation

Soft tissue features of peri‐implant diseases and related treatment

Galárraga-Vinueza

Tavelli

2022

Clin Implant Dent Rel Res

View full text Add to dashboard Cite

Background The need for soft tissue grafting at implant sites for preventing and treating peri‐implant diseases is a currently investigated and debated topic. Purpose The aim of this manuscript is to explore the inflammatory mechanisms at the peri‐implant soft tissue compartment, to distinguish the structural components of the peri‐implant soft tissue phenotype and their role on peri‐implant health, and to appraise the clinical indications and expected outcomes of soft tissue augmentation procedures at peri‐implant diseased sites. Materials and Methods This narrative review depicts the inflammatory biomarkers and mediators in the peri‐implant crevicular fluid utilized to diagnose peri‐implant disease and that have been shown to be associated with peri‐implant soft tissue phenotype modification and disease resolution. The impact of the peri‐implant soft tissue phenotype, involving keratinized mucosa (KM) width, attached mucosa (AM), mucosal thickness (MT), and supracrestal tissue height (STH), on peri‐implant health, esthetic, patient's comfort and disease prevention are discussed. The manuscript also illustrates the use of ultrasonography for the detection of peri‐implant health/disease and the evaluation of the treatment outcomes following surgical therapies. Results Current evidence indicates that soft tissue phenotype modification at implant sites with inadequate KM width, AM and MT can be beneficial for promoting peri‐implant health and improving patient's comfort and hygiene procedures. Treatment approaches and outcomes from the available literature on soft tissue phenotype modification in combination with conventional techniques at sites with peri‐implant mucositis or peri‐implantitis are presented and discussed in detail. Conclusions Soft tissue grafting can be beneficial in preventing and treating peri‐implant diseases. Clinical recommendations based on the disease, soft tissue phenotype characteristics and bone defect morphology are provided for a comprehensive hard‐ and soft‐tissue‐oriented treatment of peri‐implant disease.

show abstract

Section: Inflammatory Mechanisms and Disease Progression At The Soft ...mentioning

confidence: 99%

Section: Inflammatory Protein Biomarkersmentioning

confidence: 99%

Soft tissue features of peri‐implant diseases and related treatment

Galárraga-Vinueza

Tavelli

2022

Clin Implant Dent Rel Res

View full text Add to dashboard Cite

show abstract

“…The inclusion criteria of the study were as follows: Participants were aged between 18 and 60 years old, were generally healthy, non-smoking, and none had undergone periodontal therapy and/or antibiotic therapy in the past 6 months [ 13 ]. Patients with systemic diseases, such as diabetes mellitus, rheumatoid arthritis, and cancer, pregnant or breastfeeding women were excluded [ 14 ].…”

Section: Methodsmentioning

confidence: 99%

Salivary and serum asprosin hormone levels in the 2018 EFP/AAP classification of periodontitis stages and body mass index status: a case-control study

Gül,

Eminoğlu,

Laloğlu

et al. 2024

Clin Oral Invest

View full text Add to dashboard Cite

Objectives A newly discovered adipokine known asprosin in serum and saliva in patients with periodontitis has not been explored. The aim of this study was to determine the relationship between serum and saliva asprosin levels and periodontitis by grouping it according to body mass index (BMI). Materials and methods The study was conducted on 65 systemically healthy patients (35 patients with periodontitis (periodontitis group), 30 periodontally healthy patients (control group)). In each patient, age, BMI, and clinical periodontal parameters (plaque index (PI), gingival index (GI), probing depth (PD), and clinical attachment level (CAL)) were evaluated. Statistical analyses were conducted utilizing the Student t-test, ANOVA, and Pearson correlation analysis. For the significance level of the tests, p<0.05 were accepted. Results The serum and saliva were collected to assess asprosin levels. Both the serum and saliva asprosin levels were statistically significantly higher in the periodontitis group than in the control group (p<0.001). Saliva and serum asprosin levels were directly proportional to the severity of the periodontal disease (p<0.05). Asprosin levels were higher in patients with a higher BMI (p<0.05). Conclusion Asprosin levels were increased in periodontitis, and even a high BMI status apparently affected the levels of this hormone. It is thought that asprosin may be a useful biomarker in evaluating the relationship between periodontal status and BMI. Clinical relevance Asprosin may be a useful parameter as a biomarker of periodontal disease progression. However, BMI status should be considered when evaluating asprosin levels in patients with periodontitis.

show abstract

“…Finally, sixteen studies [16,17,19,[24][25][26][27][28][29][30][31][32][33][34][35][36] were included in the meta-analysis. Seventeen studies that were impossible to include in the meta-analysis are presented in S2 Table with details and reasons [14,15,18,[37][38][39][40][41][42][43][44][45][46][47][48][49][50] and can be considered as qualitative data. In most studies, periodontal diseases were classified based on the 1999 classification for periodontal diseases and conditions [51] and 4 studies [34,[47][48][49] based on the 2018 classification [52].…”

Section: Study Selection and Characteristicsmentioning

confidence: 99%

“…Seventeen studies that were impossible to include in the meta-analysis are presented in S2 Table with details and reasons [14,15,18,[37][38][39][40][41][42][43][44][45][46][47][48][49][50] and can be considered as qualitative data. In most studies, periodontal diseases were classified based on the 1999 classification for periodontal diseases and conditions [51] and 4 studies [34,[47][48][49] based on the 2018 classification [52]. One of the studies analyzed biopsy samples, one studied saliva, one studied saliva and serum without providing quantitative data, and one studied GCF.…”

Section: Study Selection and Characteristicsmentioning

confidence: 99%

Periodontal disease and visfatin level: A systematic review and meta-analysis

Bayani,

Heidari,

Almasi-Hashiani

2023

PLoS ONE

View full text Add to dashboard Cite

Visfatin is considered an inflammatory biomarker in periodontal disease (PD). In this meta-analysis, we aimed to evaluate the relationship between Visfatin biomarker level with PD. In this study, Medline, Scopus, Web of Science, and Google Scholar were searched. We included studies that examined visfatin levels in samples from healthy people and periodontal disease until March 2023. The quality of the selected articles was evaluated using the Newcastle-Ottawa assessment scale. Depending on heterogeneity of studies, random-effects or fixed-effect models were used to pool results and report the standardized mean difference (SMD). After screening the retrieved papers, the related data were extracted. A total of 159 studies were identified, and 16 studies were included in the meta-analysis. In 9 studies, the SMD of visfatin level of gingival crevicular fluid (GCF) in patients with chronic periodontitis (CP) and healthy individuals was 4.32 (p<0.001). In 6 studies, the SMD of salivary visfatin level in patients with CP and healthy individuals was 2.95 (p = 0.004). In addition, in five studies, the SMD of serum visfatin level in patients with CP and healthy individuals was 7.87 (p<0.001). Therefore, Visfatin levels in serum, saliva, and GCF of patients with CP were increased in comparison to healthy individuals. Comparison of visfatin levels in saliva of gingivitis patients and healthy individuals showed a significant increase of visfatin in gingivitis patients (SMD:0.57, P = 0.018), but no significant difference was observed in the mean GCF visfatin level of gingivitis patients and healthy individuals (SMD:2.60, P = 0.090). In addition, the results suggested that there is no difference between gingivitis cases compared to CP patients (SMD:3.59, P = 0.217). Visfatin levels in GCF, serum, and saliva have the potential to be used as a diagnostic biomarker of periodontitis.

show abstract

Evaluation of adipokines and inflammatory mediator expression levels in patients with periodontitis and peri-implantitis: a cross-sectional study

Cited by 7 publications

References 51 publications

Soft tissue features of peri‐implant diseases and related treatment

Soft tissue features of peri‐implant diseases and related treatment

Salivary and serum asprosin hormone levels in the 2018 EFP/AAP classification of periodontitis stages and body mass index status: a case-control study

Periodontal disease and visfatin level: A systematic review and meta-analysis

Contact Info

Product

Resources

About